AstraZeneca’s Truqap (capivasertib) has been approved for use by the National Health Service (NHS) in England and Wales, ...

Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recommended by NICE for ...

Moores Cancer Center at the University of California San Diego has received a $1 million donation from pharmaceutical company ...

The global Breast Cancer Diagnostics Market is valued at USD 19.43 Billion in 2024 and is projected to reach a value of USD ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

A review evaluated the distribution and predictive capabilities of three genomic assays for breast cancer across different ...

Targeted treatments like Roche’s trastuzumab (Herceptin) have transformed outcomes for patients with HER2-positive breast cancer. Similarly, Pfizer’s palbociclib (Ibrance), a CDK4/6 inhibitor, has ...

Pfizer and Arvinas have shared promising top-line results from a late-stage study of their investigational protein degrader vepdegestrant in a subset of breast cancer patients. The phase 3 VERITAC-2 ...